Zentalis Pharmaceuticals, Inc. (ZNTL) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-106.2%

-$0.12

vs $1.85 price

Levered DCF

-$0.05

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-9.02

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.71×	-1.3×	-3.39×	-4.5×	-22.6×	-18.1×	-17.98×	-19.83×
P/B	0.45×	0.64×	2.27×	2.45×	9.86×	6.91×	13.51×	16.91×
P/S	0×	3.19×	0×	0×	0×	0×	0×	29,924.69×
EV / EBITDA	-0.7×	-1.2×	-4.07×	-4.58×	-17.25×	-17.52×	-16.43×	-16.59×
Gross margin	0.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%
Operating margin	0.0%	-283.6%	0.0%	0.0%	0.0%	0.0%	0.0%	-169878.6%
Net margin	0.0%	-246.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-150478.6%
Current ratio	6.93×	7.32×	7.16×	7.98×	7.98×	12.07×	4.62×	4.3×
Debt / equity	0.18×	0.13×	0.1×	0.11×	0.13×	0.01×	0.04×	0×
Interest coverage	0×	0×	0×	-88.27×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-63.4%	-49.2%	-66.8%	-54.6%	-43.6%	-38.2%	-74.1%	-85.1%
Return on invested capital	-59.6%	-50.2%	-60.3%	-45.5%	-50.3%	-35.2%	-63.2%	-68.4%
Return on assets	-47.4%	-38.5%	-52.0%	-42.8%	-33.6%	-32.2%	-51.8%	-51.4%
Free cash flow yield	-129.1%	-79.4%	-21.0%	-15.6%	-4.5%	-4.1%	-4.7%	-5.8%
Earnings yield	-141.3%	-77.0%	-29.5%	-22.2%	-4.4%	-5.5%	-5.5%	-5.0%
Enterprise value	$100.6M	$224.1M	$1B	$1.1B	$3.6B	$2.1B	$767.6M	$393.8M
Net debt / EBITDA	-0.02×	-0.05×	-0.07×	-0.02×	0.07×	0.45×	1.39×	1.06×
Cash conversion cycle (days)	0	27	0	0	0	0	0	23,908